Top

Published in:

01-08-2004 | Review Article

Dose Response and Atypical Antipsychotics in Schizophrenia

Authors: Dr Bruce J. Kinon, Jonna Ahl, Virginia L. Stauffer, Angela L. Hill, Peter F. Buckley

Published in: CNS Drugs | Issue 9/2004

Abstract

Based on information from clinical trials, both the efficacy and adverse effects of conventional antipsychotics in the treatment of schizophrenia are dose related. The overlapping nature of these dose-response profiles limits the use of these agents. Atypical antipsychotics provide greater relief across the comorbid symptom domains of schizophrenia, but dose-response studies and clinical experience have revealed that some of these drugs also have dose limitations. This article reviews the dose-response relationships of the atypical antipsychotics as presented predominantly in pivotal, randomised studies (double-blind and otherwise).

Limited data indicate that clozapine shows dose-related efficacy up to 600 mg/ day in patients with treatment-resistant schizophrenia. However, higher dosages of clozapine may be associated with the risk of seizures. Risperidone demonstrates dose-related adverse events that compromise efficacy. The dose-response relationships for ziprasidone, quetiapine and aripiprazole are less well established. The efficacy of olanzapine appears to be dose related within the recommended dosage range of 10–20 mg/day, but clinical trials that have explored higher dosages suggest improved efficacy. Furthermore, the higher doses are not associated with a significantly increased incidence of adverse events.

Further studies are clearly needed to fully characterise the dose-response relationships of atypical antipsychotics.

Gardos G, Cole JO. The importance of dosage in antipsychotic drug administration: a review of dose-response studies. Psychopharmacologia 1973; 29: 221–30PubMedCrossRef

Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the treatment of psychoses. Arch Gen Psychiatry 1988; 45: 79–91PubMedCrossRef

Rifkin A, Doddi S, Karajgi B, et al. Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry 1991; 48: 166–70PubMedCrossRef

Levison DF, Simpson GM, Lo E-S, et al. Fluphenazine plasma levels, dosage, efficacy, and adverse events. Am J Psychiatry 1995; 152(5): 765–71

Dickson R, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophr Res 1999; 35: S75–86PubMedCrossRef

Halbreich U, Kinon BJ, Gilmore JA, et al. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse events. Psychoneuroendocrinology 2003; 28 Suppl. 1: 53–67CrossRef

Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry 2002; 10(5): 280–91PubMedCrossRef

Kay SR, Fisbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13(2): 261–76PubMedCrossRef

Kapur S, Remington G. Dopamine D (2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001; 50(11): 873–83PubMedCrossRef

10.

Miller DD. The clinical use of clozapine plasma concentrations in the management of treatment-refractory schizophrenia. Ann Clin Psychiatry 1996; 8: 99–109PubMedCrossRef

11.

Simpson GM, Josiassen RC, Stanilla JK, et al. Double-blind study of clozapine dose response in chronic schizophrenia. Am J Psychiatry 1999; 156(11): 1744–50PubMed

12.

Conley RR, Carpenter Jr WT, Tamminga CA. Time to clozapine response in a standardized trial. Am J Psychiatry 1997; 154(9): 1243–7PubMed

13.

Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and halopidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002; 159(2): 255–62PubMedCrossRef

14.

VanderZwaag C, McGee M, McEvoy JP, et al. Responses of patients with treatment-refractory schizophrenia to clozapine with three serum level ranges. Am J Psychiatry 1996; 153(12): 1579–84PubMed

15.

Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13(1): 25–40PubMedCrossRef

16.

Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151(6): 825–35PubMed

17.

Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995; 166(6): 712–26PubMedCrossRef

18.

Kopala LC, Good KP, Honer WG. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low-dose risperidone. J Clin Psychopharmacol 1997; 17(4): 308–13PubMedCrossRef

19.

Merlo MC, Hofer H, Gekle W, et al. Risperidone, 2 mg/day vs 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. J Clin Psychiatry 2002; 63(10): 885–91PubMedCrossRef

20.

Beasley Jr CM, Tollefson GD, Tran PV, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsycho-pharmacology 1996; 14(2): 111–23CrossRef

21.

Beasley Jr CM, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997; 7: 125–37PubMedCrossRef

22.

Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002; 59: 441–8PubMedCrossRef

23.

Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997; 54(6): 549–57PubMedCrossRef

24.

Arvanitis LA, Miller BG. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42: 233–46

25.

Goff DC, Posever T, Herz L, et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998; 18(4): 296–304PubMedCrossRef

26.

Keck P, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl) 1998; 140: 173–84CrossRef

27.

Daniel DG, Zimbroff DL, Potkin SG, etal. Ziprasidone 80 mg/ day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Neuropsychopharmacology 1999; 20(5): 491–505PubMedCrossRef

28.

Lesern MD, Zajecka JM, Swift RH. Intramuscular ziprasidone, 2mg versus 10mg, in the short-term management of agitated psychotic patients. J Clin Psychiatry 2001; 62(1): 12–8CrossRef

29.

Daniel DG, Potkin SG, Reeves KR, et al. Intramuscular (IM) ziprasidone 20mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001; 155(2): 128–34CrossRef

30.

Arato M, O’Connor R, Meltzer H. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int J Clin Psychopharmacol 2002; 17: 207–15CrossRef

31.

Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002; 63(9): 763–71PubMedCrossRef

32.

Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60(7): 681–90PubMedCrossRef

33.

Quitkin F, Rifkin A, Klein DF. Very high dosage vs standard dosage fluphenazine in schizophrenia: a double-blind study of nonchronic treatment-refractory patients. Arch Gen Psychiatry 1975; 32(10): 1276–81PubMedCrossRef

34.

McClelland HA, Farquharson RG, Leyburn P, et al. Very high dose fluphenazine decanoate: a controlled trial in chronic schizophrenia. Arch Gen Psychiatry 1976; 33(12): 1435–9PubMedCrossRef

35.

Aubree JC, Lader MH. High and very high dosage antipsychiotics: a critical review. J Clin Psychiatry 1980; 41(10): 341–50PubMed

36.

Volavka J, Cooper TB, Czobor P, et al. High-dose treatment with haloperidol: the effect of dose reduction. J Clin Psychopharmacol 2000; 20(2): 252–6PubMedCrossRef

37.

VanPutten T, Marder SR, Mintz J. A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Arch Gen Psychiatry 1990; 47(8): 754–8PubMedCrossRef

38.

Guy W, editor. ECDEU Assessment manual for psychopharmacology: publication Adm 76-338. Washington, DC, US Department of Health, Education,and Welfare, 1976: 534–7

39.

Zimbroff DL, Kane JM, Tamminga CA, et al. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 1997; 154(6): 782–91PubMed

40.

Haase H. Extrapyramidal modification of fine movements: a‘conditio sine qua non’ of the fundamental therapeutic action of neuroleptic drugs. In: Bordeleau JM, editor. Montreal, Quebec: Editions Psychiatriques, 1961: 329–53

41.

McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 1991; 48(8): 739–45PubMedCrossRef

42.

Stone CK, Garve DL, Griffith J, et al. Further evidence of a dose-response threshold for haloperidol in psychosis. Am J Psychiatry 1995; 152(8): 1210–2PubMed

43.

Kane JM. Drug therapy: Schizophrenia. N Engl J Med 1996; 334(1): 34–41PubMedCrossRef

44.

Kane JM, Rifkin A, Woerner MG, et al. Low-dose neuroleptic treatment of outpatient schizophrenics: I. preliminary results for relapse rates. Arch Gen Psychiatry 1983; 40: 893–6CrossRef

45.

Kane JM, Woerner MG, Sarantakos S. Depot neuroleptic: a comparative review of standard, intermediate, and low-dose regimens. J Clin Psychiatry 1986; 47 Suppl.: 30–3PubMed

46.

Marder SR, VanPutten T, McKenzie J, et al. Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 1984; 41: 1025–9PubMedCrossRef

47.

Marder SR, Van Putten T, Mintz J, et al. Low- and conventional-dose maintenance therapy with fluphenazine decanoate: two-year outcome. Arch Gen Psychiatry 1987; 44: 518–21PubMedCrossRef

48.

Johnson DA, Ludlow JM, Street K, et al. Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of out-patients with schizophrenia. Br J Psychiatry 1987; 151: 634–8PubMedCrossRef

49.

Hogarty GE, McEvoy JP, Munetz M, et al. Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia: results in a two-year controlled study. Arch Gen Psychiatry 1988; 45: 797–805PubMedCrossRef

50.

Kane JM, Davis JM, Schooler N, et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry 2002; 159(4): 554–60PubMedCrossRef

51.

Kinon BJ, Kane J, Johns CA, et al. Treatment of neuroleptic-resistant schizophrenic relapse. Psychopharmacol Bull 1993; 29(2): 309–14PubMed

52.

Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Disord 1982; 170: 463–7CrossRef

53.

Segraves RT. Male sexual dysfunction and psychoactive drug use: review of a common relationship. Postgrad Med 1982; 71: 227–33PubMed

54.

Halbreich U, Rojansky N, Palter S, et al. Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 1995; 57(5): 487–91

55.

Halbreich U, Palter S. Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr Bull 1996; 22(3): 447–54PubMedCrossRef

56.

Van Putten T, Marder SR, Mintz J. Serum prolactin as a correlate of clinical response to haloperidol. J Clin Psychopharmacol 1991; 11(6): 357–61PubMedCrossRef

57.

Kinon BJ, Gilmore JA, Liu H, et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003; 28: 55–68PubMedCrossRef

58.

Fischer-Cornelssen KA, Ferner UJ. An example of European multicenter trials: multispectral analysis of clozapine. Psychopharmacol Bull 1976; 12(2): 34–9PubMed

59.

Potkin SG, Fleming K, Jin Y, et al. Clozapine enhances neurocognition and clinical symptomatology more than standard neuroleptics. J Clin Psychopharmacol 2001; 21: 479–83PubMedCrossRef

60.

Meltzer HY, Anand R, Alphs L. Reducing suicide risk in schizophrenia: focus on the role of clozapine. CNS Drugs 2000; 14(5): 355–65CrossRef

61.

Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia. International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60: 82–91PubMedCrossRef

62.

Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789–96PubMedCrossRef

63.

Overall JE, Gorham DE. The brief psychiatric rating scale. Psychol Res 1961; 10: 799–812

64.

Perry PJ, Miller DD, Arndt SV, et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenia patients. Am J Psychiatry 1991; 148(2): 231–5PubMed

65.

Buckley PF, Friedman L, Krowkinski C, et al. Clinical and biochemical correlates of ‘high-dose’ clozapine therapy for treatment-refractory schizophrenia. Schizophr Res 2001; 49: 223–9CrossRef

66.

Heinrichs DW, Hanlon ET, Carpenter Jr WT. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10: 388–98PubMedCrossRef

67.

Endicott J, Spitzer RL, Fleiss JL. The global assessment scale: a procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 1978; 35: 837–44PubMedCrossRef

68.

Pacia SV, Devinsky O. Clozapine-related seizures: experience with 5629 patients. Neurology 1994; 44(12): 2247–9PubMedCrossRef

69.

Clozaril Prescribing Information. Novartis, Canada, 1997

70.

Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001; 62 Suppl. 23: 30–8

71.

Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157(6): 975–81PubMedCrossRef

72.

Wang PS, Glynn RJ, Ganz DA, et al. Clozapine use and the risk of diabetes mellitus. J Clin Psychopharmacol 2002; 22(3): 236–43PubMedCrossRef

73.

Koller E, Schneider B, Bennett K, et al. Clozapine-associated diabetes. Am J Med 2001; 11: 716–23CrossRef

74.

Janssen PAJ, Niemegeers CJE, Awouters F, et al. Pharmacology of risperidone (R64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic propertie. J Pharmacol Exp Ther 1988; 244: 685–93PubMed

75.

Megens AA, Awouters FH, Schotte A, et al. Survey on the pharmacodynamics of the new antipsychotic risperidone. Psychopharmacology (Berl) 1994; 114(1): 9–23CrossRef

76.

Bondolfi G, Dufour H, Patris M, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 1998; 155(4): 499–504PubMed

77.

Wirshing DA, Barringer Jr DM, Green MF, et al. Risperidone in treatment-refractory schizophrenia. Am J Psychiatry 1999; 156(9): 1374–9PubMed

78.

Azorin J-M, Spiegel R, Remington G, et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry 2001; 158(8): 1305–13PubMedCrossRef

79.

Emsley RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull 1999; 25(4): 721–9PubMedCrossRef

80.

Lemmens P, Brecher M, Van Baelen B. A combined analysis of double-blind studies with risperidone vs placebo and other antipsychotic agents: factors associated with extrapyramidal symptoms. Acta Psychiatr Scand. 1999; 99(3): 160–70PubMedCrossRef

81.

Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001; 22(6): 724–63PubMedCrossRef

82.

Kleinberg DL, Davis JM, de Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 1999; 19(1): 57–61PubMedCrossRef

83.

Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001; 158(5): 765–74PubMedCrossRef

84.

Csernansky JG, Mahmoud R, Brenner R, et al. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16–22PubMedCrossRef

85.

Koller EA, Cross JT, Doraiswamy PM, et al. Risperidone-associated diabetes mellitus: a pharmacovigilance study. Pharmacotherapy 2003; 23(6): 735–44PubMedCrossRef

86.

Koro CE, Fedder DO, L’Italien CJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002; 325: 243–7PubMedCrossRef

87.

Buse JB, Cavazzoni P, Hornbuckle K, et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 2003; 56: 164–70PubMedCrossRef

88.

Scandinavian Society of Psychopharmacology Committee of Clinical Investigations (UKU): The UKU side effect rating scale: scale for the registration of unwanted effects of psyhotropics. Acta Psychiatr Scand Suppl 1987; 334: 81–94

89.

Bymaster FP, Calligaro DO, Falcone JP, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14: 87–96PubMedCrossRef

90.

Bymaster FP, Nelson DL, DeLapp NW, et al. Antagonism by olanzapine of dopamine D1, serotonin 2, muscarinic, histamine HI, and alpha 1-adrenergic receptors in vitro. Schizophr Res 1999; 37(1): 107–22PubMedCrossRef

91.

Kinon BJ, Gilmore JA, Wang L. Exploration of a dose-response relationship in schizophrenia with the novel antipsychotic drug olanzapine. San Diego (CA): US Psychiatric and Mental Health Congress, 2000

92.

Kinon BJ, Ahl J, Rotelli M, et al. Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. Am J Emerg Med 2004; 22(3): 181–6PubMedCrossRef

93.

Baker RW, Kinon BJ, Liu H, et al. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol 2003 Aug; 23(4): 342–8PubMedCrossRef

94.

Lindenmayer J-P, Volavka J, Lieberman J, et al. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial. J Clin Psychopharmacol 2001; 21: 448–53PubMedCrossRef

95.

Martin J, Gomez J-C, Garcia-Bernardo E, et al. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. J Clin Psychiatry 1997; 58(11): 479–83PubMedCrossRef

96.

Tollefson GD, Birkett MA, Kiesler GM, et al. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry 2001; 49: 52–63PubMedCrossRef

97.

Basson BR, Kinon BJ, Taylor CC, et al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001; 62(4): 231–8PubMedCrossRef

98.

Kinon BJ, Basson BR, Gilmore JA. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001; 62(2): 92–100PubMedCrossRef

99.

Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002; 22(7): 841–52PubMedCrossRef

100.

Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001; 21(4): 369–74PubMedCrossRef

101.

Saller CF, Salama AL. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 1993; 112: 285–92PubMedCrossRef

102.

Velligan DI, Newcomer J, Pultz J, et al. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 2002; 53(3): 239–48PubMedCrossRef

103.

Misra LK, Erpenbach JE, Hamlyn H, et al. Quetiapine: a new atypical antipsychotic. S D J Med 1998; 51(6): 189–93PubMed

104.

Howard HR, Lowe JA, Seeger TF. Ziprasidone hydrochloride. Drugs Future 1994; 19: 560–3

105.

Zorn SH, Seeger TF, Seymour PA, et al. Ziprasidone (CP-88,059): preclinical pharmacology review. Jpn J Neuropsychopharmacol 1995; 17: 701–7

106.

Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 1995; 275: 101–13PubMed

107.

Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsycotic drug for the treatment of schizophrenia. Clin Ther 2002; 24(1): 21–37PubMedCrossRef

108.

Swift RH, Harrigan EP, Cappelleri J, et al. Validation of the behavioral activity rating scale: a novel measure of activity in agitated patients [abstract]. Eur Psychiatry 1998; 13 Suppl. 4: 292CrossRef

109.

Taylor D. Ziprasidone in the management of schizophrenia: the QT interval issue in context. CNS Drugs 2003; 17(6): 423–30PubMedCrossRef

110.

Pfizer Inc. FDA Labeling [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2001/20-85 [Accessed 2002 Mar]

111.

Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302(1): 381–9PubMedCrossRef

112.

Jordan S, Koprivica V, Chen R. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT (1A) receptor. Eur J Pharmacol 2002; 441(3): 137–40PubMedCrossRef

113.

Kelleher JP, Centorrino F, Albert MJ, et al. Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents. CNS Drugs 2002; 16(4): 249–61PubMedCrossRef

114.

Carson WH, Stock E, Saha AR, et al. Meta-analysis of efficacy of aripiprazole in the treatment of schizophrenia [abstract]. Schizophr Res 2002; 53: 186

115.

Marder SR, McQuade RD, Stock E, et al. Ariprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003; 1916: 1-14

Title: Dose Response and Atypical Antipsychotics in Schizophrenia
Authors: Dr Bruce J. Kinon
Jonna Ahl
Virginia L. Stauffer
Angela L. Hill
Peter F. Buckley
Publication date: 01-08-2004
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 9/2004
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200418090-00005

At a glance: The STEP trials

Springer Medicine

Dose Response and Atypical Antipsychotics in Schizophrenia

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2004

The Cost of Multiple Sclerosis and the Cost Effectiveness of Disease-Modifying Agents in its Treatment

What are the Treatment Options for Patients with Severe Alzheimer’s Disease?

What Place Does Naltrexone Have in the Treatment of Alcoholism?

The Bipolar Patient with Comorbid Substance Use Disorder